Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Deliberate Obfuscation

<< Previous

Bullboard Posts

Next >>

Comment by LaserStock29on Jun 14, 2022 8:22am

171 Views

Post# 34754403

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Deliberate Obfuscation

Guess we should be thankful thebfda meeting moved everything up months so to be commercial by Jan 2023 like u said eh. All those early first 12 patients didn't seem to bother fda at all. Hopefully we get the BTD and AA together or were into mid 2023 W a btd and no pps gain. Oh wait for the AA Wait for negotiations . We need final approval When does it become obvious were being suppressed

ScienceFirst wrote:
LS29 ... Yes we learn from 1993, thanks to Roger, Dr.Lilge, Dr. Jewett and we solved those issues. But looks like we create another (temporary) problem that impacted our first 12 patients. So nothing can be sure until you have clear clinical data. That's exactly the reason we hold these clinical trials; to have enough data to give the best possible picture. As of now, you cannot even tell precisely what will be these numbers. You can only hope for the best, but you're biased as you're an investor!

3y ago, you were posting that it was time to get paid! Based on what data exactly? Exrtrapolating on patients #5-6??

A drug that clearly sets new efficacy standards by more than just one-digit % and disturbs an industry, especially a stand-alone treatment in late-stage cancer indications, is worth a minimum 5B$. Go see how much are signed the jv/takeover of adjuvants to immunotherapies and what they bring in terms of added efficacy and you'll agree with this ballpark figure quite easily.

So if our 450-days (DR) are, let's say 10% higher than any other treatment, this will displace immunotherapy and shift the focus/spotlight on PDT.

But to displace an industry, you'd better have solid clinical data as scientists will have a jaw-dropping moment and will scratch their head wondering where this technology came from, when all they heard about was immunotherapy since 2006.